Sagimet Biosciences (SGMT) Income from Continuing Operations (2022 - 2026)
Sagimet Biosciences' (SGMT) quarterly Income from Continuing Operations came in at 13818000.0 in Q1 2026, up 30.91% year-on-year from 10555343.37 in Q1 2025, and down 3.37% quarter-over-quarter from 13367000.0 in Q4 2025.
Sagimet Biosciences (SGMT) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Sagimet Biosciences' Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 13818000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 30.91% year-over-year to 13818000.0 in Q1 2026; TTM through Mar 2026 was 69877000.0, a 46.13% increase from a year earlier, with the FY2025 full-year figure at 54837000.0, up 51.02% from the prior year.
- Income from Continuing Operations eased to 13818000.0 in Q1 2026 per SGMT's latest filing, from 13367000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 6694000.0 in Q1 2023 and bottomed at 82592000.0 in Q4 2024.
- The 5-year median for Income from Continuing Operations is 15128000.0 (2024), against an average of 22471312.5.
- Across the five-year window, Income from Continuing Operations tumbled 489.76% in 2023 and surged 83.82% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 11193000.0 in 2022, then tumbled by 489.76% to 66012000.0 in 2023, then declined by 25.12% to 82592000.0 in 2024, then jumped by 83.82% to 13367000.0 in 2025, then fell by 3.37% to 13818000.0 in 2026.
- Per Business Quant, the three latest SGMT Income from Continuing Operations figures stand at 13818000.0 (Q1 2026), 13367000.0 (Q4 2025), and 19956000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Sagimet Biosciences | 227.27 Mn | 227.27 Mn | - | -13.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.82 Mn |
| Dec 31, 2025 | -13.37 Mn |
| Sep 30, 2025 | -19.96 Mn |
| Jun 30, 2025 | -22.74 Mn |
| Mar 31, 2025 | -20.00 Mn |
| Dec 31, 2024 | -82.59 Mn |
| Sep 30, 2024 | -16.44 Mn |
| Jun 30, 2024 | -10.67 Mn |
| Mar 31, 2024 | -8.80 Mn |
| Dec 31, 2023 | -66.01 Mn |
| Sep 30, 2023 | -24.09 Mn |
| Jun 30, 2023 | -28.36 Mn |
| Mar 31, 2023 | -6.69 Mn |
| Dec 31, 2022 | -11.19 Mn |
| Sep 30, 2022 | -7.47 Mn |
| Jun 30, 2022 | -7.34 Mn |